Introduction: Most melanoma patients with sentinel lymph nodes (SLN) that are histologically positive for metastasis have no additional positive lymph nodes found upon completion lymph node dissection (CLND). Therefore, it has been suggested that CLND may not be required for all patients with positive SLN. This study was undertaken to determine the frequency with which nonsentinel nodes contain melanoma cells detected by RT-PCR.
INTRODUCTION
As first described by Morton et al., the sentinel lymph node (SLN) is the first node in a regional basin that receives afferent lymphatic drainage from a primary tumor [1] . Multiple studies have shown that SLN biopsy in melanoma can accurately predict the status of the regional lymph nodes. SLN biopsy can determine the presence of nodal metastases with a procedure that carries the morbidity of a lymph node biopsy, and has largely replaced elective lymph node dissection as the standard method of nodal staging. Among patients with melanomas Ն1.0 mm Breslow thickness, approximately 15 to 25% have evidence of SLN metastases detected by histology or immunohistochemical staining [1] [2] [3] [4] . Therefore, the majority of patients can avoid the morbidity of complete regional lymphadenectomy.
When a SLN is found to contain metastatic disease, a therapeutic completion lymph node dissection (CLND) is performed routinely. However, some have recently questioned the need for CLND in all patients with a positive SLN. Among patients who undergo CLND, the vast majority of patients have no additional positive nodes beyond the SLN. When CLND is per-formed, routine histopathology of each node in the specimen is performed, as it is impractical and expensive to perform serial sectioning and immunohistochemical staining of all nonsentinel nodes. Although the rate of nonsentinel nodal metastasis is relatively low, the risk of recurrence in the nodal basin is unknown when CLND is not performed. In a recent study, Reintgen and colleagues found that the nonsentinel nodes never contained histologic evidence of metastases in patients with primary melanomas less than 2.8 mm Breslow thickness [5] . However, conflicting data exist; a recent analysis of the Sunbelt Melanoma Trial, a multicenter study of SLN biopsy and adjuvant therapy, failed to identify a patient population with minimal risk of residual disease in the CLND specimen, even among patients with tumors 1.0 to 2.0 mm thick [6] .
One important factor in determining the status of the nodes is the method of pathologic evaluation. Standard pathologic examination involves one or two sections from the center of the node with routine hematoxylin and eosin (H&E) staining. This evaluates less than 1% of the total nodal tissue. Some studies have shown that routine histologic evaluation of regional nodes can fail to detect as much as 50% of metastatic disease because micrometastases are often missed by routine histopathology [7] . With SLN biopsy, the one or two nodes most likely to contain metastasis are submitted for histologic evaluation. This allows for a more detailed examination of the node or nodes most likely to harbor metastatic disease with serial sectioning and immunohistochemical staining. However, CLND specimens are typically examined with standard histopathology and may miss micrometastatic disease.
Molecular staging by reverse transcriptase polymerase chain reaction (RT-PCR) can detect mRNA that are expressed specifically in cancer cells. For example, tyrosinase is an enzyme involved in the synthesis of melanin pigment in melanocytes and melanoma cells, and is not commonly expressed in normal lymph nodes. Use of RT-PCR to detect tyrosinase mRNA has been applied in many studies as a marker for melanoma cells [8 -11] . Lymph nodes that are histologically positive for melanoma are RT-PCR positive in 94 to 100% of cases [10, 12] . RT-PCR has also been shown to detect melanoma cells in patients with histologically negative nodes. Reintgen and colleagues have demonstrated that RT-PCR analysis detects occult melanoma cells in SLN, which correlates with worse disease-free and overall survival [10, 11] . Use of additional molecular markers have further enhanced detection of micrometastatic disease. Studies have evaluated MART-1, MAGE-3, and gp100 in detection of melanoma metastasis both in circulating peripheral blood cells and in the SLN [13] [14] [15] .
The present study was conducted to determine, among patients undergoing CLND for a positive SLN, the frequency of submicroscopic metastases in histologically negative nonsentinel nodes using RT-PCR analysis. This will provide some insight into the spread of melanoma cells beyond the SLN.
METHODS
Patients were enrolled in an IRB approved protocol at the University of Louisville Affiliated Hospitals between April 1998 and October 2000. Patients undergoing CLND for a positive SLN were eligible for the study. Negative control lymph nodes were obtained from patients with breast (N ϭ 98) and colon cancer (N ϭ 2). Positive control lymph nodes contained gross and/or histologic evidence of melanoma. Nonsentinel nodes were harvested from melanoma patients undergoing CLND for a histologically positive SLN. A 2 mm 3 piece of each lymph node was snap-frozen on dry ice. RT-PCR analysis for melanoma markers tyrosinase, gp100, MART-1, and MAGE-3 was performed, with Southern blot detection as described previously. Only patients who had histologically negative non-SLN were included in this study. The RT-PCR test was considered positive for the presence of melanoma cells if tyrosinase and at least one other marker were detected above background levels. This definition is used for SLN evaluation in the Sunbelt Melanoma Trial, and was derived from analysis of multiple blood and lymph node samples at the National Genetics Institute to provide optimal specificity for the presence of melanoma cells and minimization of false-positive results.
Statistical analysis was performed by Student's t-test and 2 analysis, with significance at P Ͻ 0.05.
RESULTS
Characteristics of CLND patients who underwent RT-PCR analysis are shown in Table 1 . A total of 117 histologically negative nonsentinel nodes from 13 patients who underwent CLND for a positive SLN were evaluated.
RT-PCR analysis revealed detectable levels of tyrosinase, gp100, MART-1, and MAGE-3 in 1, 0, 0, and 6% of negative control lymph nodes from patients with breast and colon cancer, respectively (Table 2 ). This represents some degree of nonspecific expression of these mRNA in normal nodes. However, when the def- inition of an RT-PCR-positive lymph node is applied (the presence of tyrosinase plus at least one other marker), no negative control lymph nodes were positive for the presence of melanoma cells. RT-PCR testing was positive in 28/29 (97%) of positive control lymph nodes with gross and/or histologic evidence of melanoma (Table 2 ). Among patients with histologically negative nonsentinel nodes from CLND specimens, RT-PCR analysis was positive in 18/117 nodes (15%) from 7/13 patients (54%; Table 2 ). The differences in rates of RT-PCR-positive nonsentinel nodes were statistically significant (P Ͻ 0.0001, positive control LN and nonsentinel nodes vs negative control nodes;
2 ). Table 3 shows the tumor thickness and frequency of RT-PCR-positive markers by individual patients. There was no statistically significant difference in the mean Breslow thickness for patients with RT-PCR positive (2.20 mm) or negative (2.02 mm) nonsentinel nodes. Tyrosinase as a single marker was positive in 4/58 lymph nodes (7%) among 3/6 patients defined as having RT-PCR-negative nonsentinel nodes (Table 4) .
DISCUSSION
RT-PCR analysis of lymph nodes is a very sensitive test that can detect one melanoma cell in 1 million normal cells [16, 17] . The detection of melanoma cells in SLN by RT-PCR for tyrosinase mRNA analysis correlates with worse disease-free and overall survival. Li et al. report a 37% recurrence in patients with histologically positive SLN, but only a 2% recurrence if histologically negative [11] . The addition of RT-PCR to this study showed a 10% recurrence in patients with histologically and immunohistochemically negative, RT-PCR-positive SLN. Shivers et al. showed that patients with SLN positive only by RT-PCR for tyrosinase had a 13% recurrence rate, as compared to 2% if both histologically and RT-PCR negative [10] . Therefore, detection of occult melanoma cells in SLN by RT-PCR analysis appears to correlate with increased risk of recurrence.
It has been suggested that molecular staging is too sensitive and that RT-PCR analysis may provide falsepositive results. Reintgen et al. noted that benign nevus cell rests can be found in normal lymph nodes, which may lead to false-positive tyrosinase RT-PCR testing in 5% of patients or more [10, 11] . We utilized a multimarker RT-PCR assay in order to maximize specificity and minimize the risk of false-positive results. RT-PCR testing was positive for the presence of melanoma cells in 0 and 97% of the negative and positive control lymph nodes, respectively. This suggests that the assay is sensitive and specific for the detection of melanoma cells, and that our definition of a positive RT-PCR test is appropriate. Only 1% of the negative control lymph nodes was positive by tyrosinase alone. Presumably, our negative control nodes contained the typical frequency of benign nevus cell rests seen in the general population, although this was not examined specifically on histopathology. Overall, 6% of the negative control lymph nodes were positive for MAGE-3 mRNA expression (all from breast cancer patients). MAGE-3 mRNA has been shown to be expressed in breast cancer. Therefore, it is not possible to determine if MAGE-3 expression seen in our "negative control" nodes is related to the presence of occult breast cancer cells, as opposed to baseline expression in normal nodal tissue [18] . Tyrosinase expression as a single marker was identified in 4/58 lymph nodes (7%) among 3/6 patients (50%) with RT-PCR negative non-SLN. Using our definition of a positive RT-PCR test, these nodes are considered to be negative for tumor. The 7% expression of tyrosinase in this group is certainly higher than the 1% rate of tyrosinase positivity seen in the negative control group. It is possible that tyrosinase expression in these patients represents the presence of melanoma cells that could not be confirmed using the other markers.
Because RT-PCR analysis in this study was performed on a random sample (approximately a 2 mm 3 portion of each lymph node) there is also the potential of sampling error that could result in underestimation of the number of lymph nodes that contain melanoma cells. Because the nodes must be examined histologically, only a portion can be evaluated by RT-PCR, and any sample is by definition a random sample. The possibility exists, however, that examination of larger portions of each node, or the entire node, would result in increased detection melanoma cells by RT-PCR.
RT-PCR analysis of nonsentinel lymph nodes may improve our ability to predict which patients are at higher risk for recurrence. The current literature indicates that only 15 to 22% of the patients undergoing CLND after a positive SLN have evidence of metastatic disease [19, 20] . Our data suggest that the actual frequency of occult disease in the nonsentinel nodes may be higher, and that CLND may benefit more patients than previously thought. It is not possible, at present, to determine how often patients with RT-PCR-positive nonsentinel nodes would recur in the nodal basin if untreated. It is likely that not all melanoma cells detected by RT-PCR are destined to form tumors, and that some cancer cells might be cleared naturally by the immune system or other mechanisms. However, the true risk of nodal recurrence among patients with histologically positive SLN, if CLND is not performed, can only be established by long-term follow-up of patients who do not undergo CLND.
It may be possible to use prognostic factors of the primary melanoma to predict which patients are more likely to have nonsentinel nodal metastases detected by RT-PCR or other methods. Because of the small number of patients in the present study, such an analysis was not possible. However, it is interesting to note that 4 of the 7 patients with RT-PCR-positive nonsentinel nodes had melanomas less than 2 mm Breslow thickness.
Adjuvant therapy with interferon ␣-2b has been shown to improve disease-free (3/3 studies) and overall (2/3 studies) survival for patients with high-risk melanoma [21] [22] [23] . Whether or not adjuvant interferon ␣-2b is effective in reducing the risk of nodal metastasis among patients with a positive SLN who do not undergo completion lymph node dissection is not known, and this may be an appropriate subject for future clinical trials. Furthermore, it is not known how many patients who recur in the regional lymph nodes could be salvaged by therapeutic lymph node dissection if such a strategy were employed. Until such information is available, we recommend completion lymph node dissection for patients with a positive sentinel node because of the substantial risk of residual histologically positive [6] , as well as RT-PCR-positive, lymph nodes.
Therefore, in keeping with the results of patients with RT-PCR-positive sentinel nodes, it stands to reason that RT-PCR detection of melanoma cells in the nonsentinel nodes may represent clinically meaningful disease, and may predict a higher risk of recurrence if CLND is not performed. When the SLN is histologically positive, RT-PCR analysis suggests that the remaining nodes in that basin are at risk for metastatic disease, despite the fact that these nonsentinel nodes are infrequently histologically positive. Outside of a clinical trial, CLND should be performed routinely for patients with histologic evidence of metastasis in the SLN.
